Association of the A870G cyclin D1 gene polymorphism with genetic susceptibility to nasopharyngeal carcinoma

被引:34
作者
Catarino, Raquel J.
Breda, Eduardo
Coelho, Vania
Pinto, Daniela
Sousa, Hugo
Lopes, Carlos
Medeiros, Rui
机构
[1] Inst Portugues Oncol Francisco Gentil, Mol Oncol Unit, P-4200072 Oporto, Portugal
[2] Portuguese Inst Oncol, Otorrinolaringol Dept, Oporto, Portugal
[3] ICBAS, Abel Salazar Inst Biomed Sci, Oporto, Portugal
来源
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK | 2006年 / 28卷 / 07期
关键词
cyclin D1; genetic polymorphism; nasopharyngeal cancer; head and neck; cancer risk;
D O I
10.1002/hed.20377
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 [耳鼻咽喉科学];
摘要
Background. Nasopharyngeal cancer (NPC) is multifactorial, and the genetic background may be a crucial etiologic factor. Cyclin D1 (CCND1) is a key regulator of the cell cycle, and its altered activity is associated with the development of cancer. Methods. We analyzed the A870G CCND1 polymorphism by polymerase chain reaction/restriction fragment length polymorphism (PCR-RFLP) in 281 individuals, including 94 patients with NPC and 187 healthy individuals. Results. Our results indicate that individuals carrying two G alleles have a 2.17-fold increase in the risk for the development of NPC (odds ratio [OR], 2.17; 95% confidence interval [Cl], 1.19-3.98; p =.016). Age-adjusted logistic regression analysis confirmed this association (adjusted odds ratio [aOR], 2.14; 95% Cl, 1.14-4.04; p =.018). Multivariate analysis demonstrates an independent association between GG CCND1 genotype (aOR, 2.06), male sex (aOR, 2.66), and age at diagnosis (aOR, 2.02) regarding the development of undifferentiated NPC. The proportion of NPC cases attributable to the GG CCND1 genotype was 14,76%. Conclusions. Our results may be important in the definition of a biologic predictive profile for the development of NPC within ourpopulation. (c) 2006 Wiley Periodicals, Inc.
引用
收藏
页码:603 / 608
页数:6
相关论文
共 44 条
[1]
BETTICHER DC, 1995, ONCOGENE, V11, P1005
[2]
Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer [J].
Betticher, DC ;
Heighway, J ;
Hasleton, PS ;
Altermatt, HJ ;
Ryder, WDJ ;
Cerny, T ;
Thatcher, N .
BRITISH JOURNAL OF CANCER, 1996, 73 (03) :294-300
[3]
CALLENDER T, 1994, CANCER-AM CANCER SOC, V74, P152, DOI 10.1002/1097-0142(19940701)74:1<152::AID-CNCR2820740124>3.0.CO
[4]
2-K
[5]
Increased risk of cervical cancer associated with cyclin D1 gene A870G polymorphism [J].
Catarino, R ;
Matos, A ;
Pinto, D ;
Pereira, D ;
Craveiro, R ;
Vasconcelos, A ;
Lopes, C ;
Medeiros, R .
CANCER GENETICS AND CYTOGENETICS, 2005, 160 (01) :49-54
[6]
Increased cell growth and tumorigenicity in human prostate LNCaP cells by overexpression to cyclin D1 [J].
Chen, Y ;
Martinez, LA ;
LaCava, M ;
Coghlan, L ;
Conti, CJ .
ONCOGENE, 1998, 16 (15) :1913-1920
[7]
Cho EY, 2003, CANCER EPIDEM BIOMAR, V12, P1100
[8]
Protective role of the polymorphism CCR2-64I in the progression from squamous intraepithelial lesions to invasive cervical carcinoma [J].
Coelho, A ;
Matos, A ;
Catarino, R ;
Pinto, D ;
Pereira, D ;
Lopes, C ;
Medeiros, R .
GYNECOLOGIC ONCOLOGY, 2005, 96 (03) :760-764
[9]
TP73 alterations in cervical carcinoma [J].
Craveiro, R ;
Costa, S ;
Pinto, D ;
Salgado, L ;
Carvalho, L ;
Castro, C ;
Bravo, I ;
Lopes, C ;
Silva, I ;
Medeiros, R .
CANCER GENETICS AND CYTOGENETICS, 2004, 150 (02) :116-121
[10]
DENG L, 2002, SHENG WU HUA XUE YU, V1, P16